Mice were first challenged subcutaneously with C1498-luc, and 7-days later, when tumours reached a size of 3–5 mm diameter the mice received PLK1-derived peptide-loaded DC prime_TriVax booster immunisation with a 7-day interval. The gene discussed is PLK1; the disease is neoplasm.